BACKGROUND Acute nonvariceal upper gastrointestinal bleeding(ANVUGIB)is a frequent lifethreatening acute condition in gastroenterology associated with high morbidity and mortality.Over-the-scope-clip(OTSC)is a new end...BACKGROUND Acute nonvariceal upper gastrointestinal bleeding(ANVUGIB)is a frequent lifethreatening acute condition in gastroenterology associated with high morbidity and mortality.Over-the-scope-clip(OTSC)is a new endoscopic hemostasis technique,which is being used in ANVUGIB and is more effective.AIM To summarize and analyze the effects of the OTSC in prevention of recurrent bleeding,clinical success rate,procedure time,hospital stay,and adverse events in the treatment of ANVUGIB,to evaluate whether OTSC can replace standard endoscopic therapy as a new generation of treatment for ANVUGIB.METHODS The literature related to OTSC and standard therapy for ANVUGIB published before January 2023 was searched in PubMed,Web of Science,EMBASE,Cochrane,Google,and CNKI databases.Changes in recurrent bleeding(7 or 30 days),clinical results(clinical success rate,conversion rate to surgery,mortality),therapy time(procedure time,hospital stay),and adverse events in the OTSC intervention group were summarized and analyzed,and the MD or OR of 95%CI is calculated by Review Manager 5.3.RESULTS This meta-analysis involved 11 studies with 1266 patients.Total risk of bias was moderate-to-high.For patients in the OTSC group,7-and 30-days recurrent bleeding rates,as well as procedure time,hospital stay,and intensive care unit stay,were greatly inhibited.OTSC could significantly improve the clinical success rate of ANVUGIB.OTSC therapy did not cause serious adverse and was effective in reducing patient mortality.CONCLUSION OTSC may provide more rapid and sustained hemostasis,and thus,promote recovery and reduce mortality in patients with ANVUGIB.In addition,the safety of OTSC is assured.展开更多
文摘BACKGROUND Acute nonvariceal upper gastrointestinal bleeding(ANVUGIB)is a frequent lifethreatening acute condition in gastroenterology associated with high morbidity and mortality.Over-the-scope-clip(OTSC)is a new endoscopic hemostasis technique,which is being used in ANVUGIB and is more effective.AIM To summarize and analyze the effects of the OTSC in prevention of recurrent bleeding,clinical success rate,procedure time,hospital stay,and adverse events in the treatment of ANVUGIB,to evaluate whether OTSC can replace standard endoscopic therapy as a new generation of treatment for ANVUGIB.METHODS The literature related to OTSC and standard therapy for ANVUGIB published before January 2023 was searched in PubMed,Web of Science,EMBASE,Cochrane,Google,and CNKI databases.Changes in recurrent bleeding(7 or 30 days),clinical results(clinical success rate,conversion rate to surgery,mortality),therapy time(procedure time,hospital stay),and adverse events in the OTSC intervention group were summarized and analyzed,and the MD or OR of 95%CI is calculated by Review Manager 5.3.RESULTS This meta-analysis involved 11 studies with 1266 patients.Total risk of bias was moderate-to-high.For patients in the OTSC group,7-and 30-days recurrent bleeding rates,as well as procedure time,hospital stay,and intensive care unit stay,were greatly inhibited.OTSC could significantly improve the clinical success rate of ANVUGIB.OTSC therapy did not cause serious adverse and was effective in reducing patient mortality.CONCLUSION OTSC may provide more rapid and sustained hemostasis,and thus,promote recovery and reduce mortality in patients with ANVUGIB.In addition,the safety of OTSC is assured.
文摘目的·分析急性非静脉曲张性上消化道出血(acute nonvariceal upper gastrointestinal bleeding,ANVUGIB)患者再出血的独立危险因素,构建再出血预测模型及风险评分系统。方法·收集2016年1月1日至2019年12月31日苏州大学附属第一医院收治的686例ANVUGIB患者的病例资料,记录患者的一般情况、临床表现、实验室检查结果、内镜下表现、病情转归等,并计算所有患者的内镜前Baylor、内镜后Baylor、Rockall、GBS (Glasgow Blatchford Score)、CSMCPI (Cedars-Sinai Medical Center Predictive Index)、AIMS65、MAP (ASH)评分。将所收集的病例按7∶3随机分成建模组(n=481)和验证组(n=205),使用建模组数据建立模型。将单因素分析中有意义的变量(P<0.1)纳入Logistic回归分析,探究再出血的独立危险因素,构建再出血风险预测模型并进行内部验证,分别评价建模组及验证组的区分度及校准度,最终将模型转换为风险评分系统。受试者操作特征(receiver operating characteristic,ROC)曲线效能的比较采用Delong统计法。结果·低收缩压,低血红蛋白水平,美国麻醉医师协会(American Society of Anesthesiologists,ASA)分级>3级,内镜下呈现为血凝块、血管裸露、活动性出血是再出血的独立危险因素。预测模型的ROC曲线下面积(area under the curve,AUC)为0.892 (95%CI 0.838~0.946,P=0.001),Hosmer-Lemeshow检验P=0.934;内部验证AUC=0.915 (95%CI 0.851~0.980,P=0.001);Hosmer-Lemeshow检验P=0.871。该风险评分系统的AUC=0.882 (95%CI 0.823~0.942),对再出血的预测能力优于除MAP (ASH)评分以外的其余各项评分(均P<0.05)。结论·该研究建立的评分系统对ANVUGIB再出血具有良好的预测能力,具有一定的临床应用价值。
